Learn More
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates complement and antibody-dependent cell-mediated cytotoxicity and has direct antiproliferative effects against malignant B-cell lines in vitro. Phase I trials of single doses up to 500 mg/m2 and 4(More)
Human anti-murine immunoglobulin responses were assessed in serum from three groups of patients receiving murine monoclonal antibody therapy. Each of the three patient groups responded differently. Chronic lymphocytic leukemia patients demonstrated little or no preexisting murine immunoglobulin G-reactive antiglobulin prior to treatment, while the cutaneous(More)
Colorectal cancer represents 10% of all cancers and 10% of cancer deaths in the United States with ϳ130,000 new cases diagnosed annually (1). There have been important advances in our understanding of the biology and genetics of this disease, and if diagnosed early, colorectal cancer is highly curable. Patients with Dukes' A colon cancer that invades only(More)
O scatter plot than on traditional forward side-scatter gating (Fig 1). VER A DECADE HAS passed since ''Immunologic Classification of Leukemia and Lymphoma'' by Foon and Todd was published in Blood. 1 Over this decade, flow Acute myeloid leukemia (AML). AML is traditionally subclassified by morphology and cytochemistry according cytometry has evolved from a(More)
Minor histocompatibility antigens (mHAg's) are peptides encoded by polymorphic genes that are presented by major histocompatibility complex (MHC) molecules and recognized by T cells in recipients of allogeneic hematopoietic cell transplants. Here we report that an alternative transcript of the proliferation-associated nuclear element 1 (PANE1) gene encodes(More)
PURPOSE Radioimmunotherapy has been approved for relapsed follicular lymphoma (FL), including rituximab-refractory FL. This study was designed to determine the CR rate with short-course chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended rituximab as(More)